About nuvision-logo-white

About Us

NuVision® is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. The founder of NuVision®, Dr Andrew Hopkinson is the Principal Research Fellow in Academic Ophthalmology within the Division of Clinical Neuroscience at the University of Nottingham. The business is co-owned by the founders, Dr Andrew Hopkinson (CEO), Professor Harminder Dua (Clinical Director), the directors Mr Bryan Lister (COO), Dr Helen Shaw (Medical director) and the University of Nottingham.

Dr Andrew Hopkinson


We are here

Where We Are

NuVision is based at MediCity, Nottingham and GMP manufacturing laboratories, regulated by the Human Tissue Authority (HTA), will came online in Autumn 2015. NuVision™ evolved from an academic translational research group whose success is emphasised and underpinned by a significant track record in scientific publications and presentations, sustained charity grant support and collaborative contracts with industrial (Government) organisations of up to £2 million.

How We’re Funded

Mercia Fund Management (MFM), a national fund management business has committed £379,000 in seed funding to NuVision Biotherapies Ltd, to develop effective and affordable eye care medical solutions for humans and animals. In addition, we have secured funding of £70,000 from the University of Nottingham’s Innovation Board to establish Omnigen™ manufacturing. This has been supported by £75k of Nottingham Council Technology Fund (N’Tech) and most recently dual Innovate UK funding in the form of a £25k Smart Proof of Market & £150k Biomedical Catalyst feasibility study award.

Why We’re Special

The USP of NuVision is that we were formed from, and are supported by, a world leading corneal research group whose aim is to address key clinical challenges to provide solutions to sight saving problems. This is the UK’s first ophthalmic biotech, backed by such a prestigious academic research group. The company’s launch product is Omnigen™, a biological wound dressing which aids the regeneration and healing of the surface of the eye. Omnigen™ is a ‘first of its kind’ human amniotic membrane-derived dry preserved biological matrix intended for ocular surface surgical and trauma therapy.

Interested in purchasing Omnigen?

Register your interest

Click Here

Have a question about our products or pipelines?

Speak to our team of experts

Click Here